Physician profile
Grayson Woods
NPI 1346345881
$4,022.52
in general payments reported to CMS, 2019-2025
28 companies · $490 in 2025
The $490 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $547 · 2021: $553 · 2022: $608 · 2023: $580 · 2024: $445 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.60 | 2019-2025 | |
| Pfizer INC. | $420.53 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $378.90 | 2021-2025 | |
| Allergan, INC. | $362.00 | 2019-2022 | |
| Merz North America, INC. | $335.75 | 2020 | |
| Galderma Laboratories, L.P. | $301.98 | 2019-2023 | Dysport |
| Revance Therapeutics, INC. | $247.03 | 2024-2025 | Daxxify |
| Daiichi Sankyo INC. | $214.97 | 2019-2022 | |
| Astellas Pharma US INC | $205.08 | 2024-2025 | Veozah |
| Millicent US INC | $100.81 | 2022-2025 | Intrarosa, Femring |
| Ascend Therapeutics US, LLC | $96.85 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.44 | 2019-2025 | |
| Therapeuticsmd, INC. | $88.26 | 2019-2022 | |
| Exeltis, USA INC. | $84.01 | 2024-2025 | Slynd |
| Coopersurgical, INC. | $50.29 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $41.20 | 2019-2023 | Novasure |
| Mylan Pharmaceuticals INC. | $36.25 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $31.33 | 2025 | Myfembree |
| Minerva Surgical, INC | $30.97 | 2019-2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $30.97 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $28.80 | 2019 | |
| Covidien Lp | $23.38 | 2019 | |
| Duchesnay USA Incorporated | $23.35 | 2019 | |
| Scynexis, INC. | $20.94 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.26 | 2019 | |
| Lupin INC. | $15.40 | 2019 | |
| Virtus Pharmaceuticals LLC | $15.03 | 2022 | |
| Merck Sharp & Dohme LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grayson Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.